Inflamax Research - page 4

The company’s specializations are nu-
merous: asthma, dry eye syndrome, al-
lergy, and more. The latter, in particular,
is an affliction endured by a vast number
of people around the world. With a back-
ground in biochemistry, physiology and
pharmacology, Dr. Anne Marie Salapatek,
Inflamax’s President and Chief Science Of-
ficer, knows better than anyone about the
detrimental effects of allergies. Though re-
garded as a commonplace ailment, aller-
gies can lead the way to other diseases
like asthma, and severe allergic reactions
can cause anaphylaxis and even death.
“The World Health Organization has indi-
cated that allergy is increasing in epidemic
proportions. We really have to understand
the mechanisms behind this if we’re going
to understand how to avoid it or minimize
it,” Dr. Salapatek said.
“We have built our company organically and grown it organically and we’ve
really tried to employ managers who have good leadership skills.”
Dr. Anne Marie Salapatek, President & CSO
4
business elite canada
H
APRIL 2016
1,2,3 5,6,7,8,9,10
Powered by FlippingBook